



FOR IMMEDIATE RELEASE

## **Immgenuity Inc., Announces the Appointment of Jürgen Rockstroh, MD, Renowned Infectious Diseases Expert, to its Scientific Advisory Board**

Dover, Delaware, February 12, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Jürgen Rockstroh has joined its Scientific Advisory Board.

Dr. Rockstroh is a world-renowned expert in infectious diseases, with a distinguished career spanning over three decades. He is currently Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn in Germany. He has also served as the President of the International AIDS Society and has been a leading voice in the global fight against HIV/AIDS. He has authored numerous scientific publications and has served on advisory boards for various organizations, including the World Health Organization and the European AIDS Clinical Society.

“We are excited to welcome Dr. Jürgen Rockstroh to Immgenuity's Scientific Advisory Board. Dr. Rockstroh's expertise in infectious diseases, particularly in the field of HIV/AIDS, will be invaluable as we continue to develop novel immunotherapies to tackle some of the most challenging aspects of HIV, particularly our therapeutic immunotherapy, IMTV014”, said Dr. Sateesh Apte, CEO of Immgenuity, Inc.

“I am honored to join Immgenuity's Scientific Advisory Board. The company's pioneering work in harnessing the immune system's power for therapeutic applications has the potential to revolutionize the treatment of HIV infection. I am excited to contribute my expertise in infectious diseases to advance Immgenuity's mission of developing breakthrough immunotherapies to improve patient outcomes”, said Dr. Jürgen Rockstroh.

### **About Immgenuity, Inc.**

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

### **About IMTV014**

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

Contact: Media Relations: [media@immgenuity.com](mailto:media@immgenuity.com) (302) 321-5844

**Forward Looking Statements:**

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.